Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States ow.ly/Z5kH50S3YI1 #clinicaltrialsandobservations #thrombosisandhemostasis

.George Goshua, MD MSc accepts the prestigious NOMIS and Science Magazine Young Explorer Award in Zurich, Switzerland. Read more about Dr. Goshua and his winning essay "Napkin math can change the world." yalecancercenter.org/news-article/d… Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp YaleHematology

Thank you Yale Cancer Center -> our trainees = why we do this: 4 most recent (May & June 2024) first-author trainee 🌟s Yale School of Medicine Yale Internal Medicine Johns Hopkins Hematology & NIH Critical Care Medicine Christina Waldron Satoko Ito, MD PhD #cecilyallen #danielwang Ayesha Butt, MD Rhys Richmond Harlan Krumholz Hanny Al-Samkari, MD Adam Cuker MD, MS

Excited to see this article with George Goshua, MD MSc out in Bulletin of the Atomic Scientists, where we explore how adding a health equity lens to valuation can help harness the potential of gene therapies around the world Yale School of Medicine Yale Internal Medicine Yale IM Traditional Residency Program Mark D. Siegel

Study evaluates the conventional and distributional cost-effectiveness of prophylaxis with efanesoctocog alfa versus standard-care factor VIII (standard half-life and extended half-life) for patients living with severe hemophilia A in the United States. Read more at